EBOS details basis of half-year underlying earnings and non-GAAP measures

EBOS Group Limited ( (AU:EBO) ) has shared an update.

EBOS Group has released a presentation outlining key financial reporting parameters and disclaimers for its half-year results to 31 December 2025. The company emphasises that the material is a summary only, may contain non-GAAP financial measures, and should be read alongside its audited consolidated financial statements, with users warned not to rely solely on these metrics.

The release clarifies that underlying earnings figures exclude various one-off items such as M&A transaction costs, restructuring and site transition expenses, and non-cash amortisation from purchase price accounting. It also notes that the latest underlying results remove the non-cash gain from the step acquisition of Origin Biologics, signalling an effort to present a clearer view of recurring performance for investors and other stakeholders.

The most recent analyst rating on (AU:EBO) stock is a Hold with a A$26.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.

More about EBOS Group Limited

EBOS Group Limited is a diversified healthcare and animal care company operating across Australia and New Zealand. The Group focuses on pharmaceutical distribution, medical and healthcare products, and related services, and it also manages a portfolio of animal health brands, positioning itself as a major regional player in both human and animal health markets.

Average Trading Volume: 136,505

Technical Sentiment Signal: Sell

Current Market Cap: A$4.29B

Learn more about EBO stock on TipRanks’ Stock Analysis page.